US4902505A
(en)
*
|
1986-07-30 |
1990-02-20 |
Alkermes |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
US6440928B1
(en)
|
1988-12-06 |
2002-08-27 |
Colorado State University Research Foundation |
Method for treating diabetic neuropathy with NGF
|
US6723699B1
(en)
*
|
1989-06-05 |
2004-04-20 |
Cephalon, Inc. |
Treating disorders by application of insulin-like growth factors and analogs
|
US5093317A
(en)
*
|
1989-06-05 |
1992-03-03 |
Cephalon, Inc. |
Treating disorders by application of insulin-like growth factor
|
US6693076B1
(en)
*
|
1989-06-05 |
2004-02-17 |
Cephalon, Inc. |
Treating disorders by application of insulin-like growth factors and analogs
|
US5652214A
(en)
*
|
1989-06-05 |
1997-07-29 |
Cephalon, Inc. |
Treating disorders by application of insulin-like growth factors and analogs
|
CA2063271A1
(en)
*
|
1989-07-14 |
1991-01-15 |
Subramonia Pillai |
Cytokine and hormone carriers for conjugate vaccines
|
JP3187410B2
(ja)
|
1989-08-10 |
2001-07-11 |
住友製薬株式会社 |
脳内投与用徐放性製剤
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US5624898A
(en)
|
1989-12-05 |
1997-04-29 |
Ramsey Foundation |
Method for administering neurologic agents to the brain
|
US6407061B1
(en)
*
|
1989-12-05 |
2002-06-18 |
Chiron Corporation |
Method for administering insulin-like growth factor to the brain
|
US6949505B1
(en)
|
1991-03-11 |
2005-09-27 |
Curis, Inc. |
Morphogen-induced dendritic growth
|
US6077823A
(en)
*
|
1991-03-11 |
2000-06-20 |
Creative Biomolecules, Inc. |
Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US6033884A
(en)
*
|
1992-03-20 |
2000-03-07 |
Baylor College Of Medicine |
Nucleic acid transporter systems and methods of use
|
EP0632722A4
(de)
*
|
1992-03-20 |
1997-07-30 |
Baylor College Medicine |
In form-imc-beschichtungsverfahren mit doppelaushaertung zur herstellung von abriebfesten,beschichteten,thermoplastischen gegenstaenden.
|
US20070078089A1
(en)
*
|
1992-07-06 |
2007-04-05 |
Ishii Douglas N |
Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II
|
US5981194A
(en)
*
|
1992-07-10 |
1999-11-09 |
University Of British Columbia |
Use of p97 and iron binding proteins as diagnostic and therapeutic agents
|
EP0599303A3
(de)
*
|
1992-11-27 |
1998-07-29 |
Takeda Chemical Industries, Ltd. |
Peptide-Konjugate
|
ATE228832T1
(de)
*
|
1994-02-28 |
2002-12-15 |
Nanopharm Ag |
System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
KR19990063632A
(ko)
*
|
1995-09-21 |
1999-07-26 |
디 헤이쓰, 산드라 우드 |
약물 운송용 트란스사이토시스 매개체 및 상승제
|
GB9526733D0
(en)
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
US6214796B1
(en)
|
1996-03-22 |
2001-04-10 |
The General Hospital Corporation |
Administration of polypeptide growth factors following central nervous system ischemia or trauma
|
US6942963B1
(en)
|
1997-01-10 |
2005-09-13 |
Massachusetts Institute Of Technology |
Methods for identifying treatments for neurotoxicity in Alzheimer's disease caused by β-amyloid peptides
|
EP1015013A4
(de)
|
1997-01-10 |
2002-07-24 |
Massachusetts Inst Technology |
Behandlung von neurotoxizität in alzheimer'schen krankheit durch beta-amyloid peptiden
|
WO1999000150A2
(en)
*
|
1997-06-27 |
1999-01-07 |
Regents Of The University Of California |
Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
|
US6501188B1
(en)
*
|
1997-07-03 |
2002-12-31 |
Micron Technology, Inc. |
Method for improving a stepper signal in a planarized surface over alignment topography
|
US7273618B2
(en)
*
|
1998-12-09 |
2007-09-25 |
Chiron Corporation |
Method for administering agents to the central nervous system
|
US6716452B1
(en)
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US7060708B2
(en)
*
|
1999-03-10 |
2006-06-13 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US7169889B1
(en)
|
1999-06-19 |
2007-01-30 |
Biocon Limited |
Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
|
CA2405709A1
(en)
*
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US6946134B1
(en)
|
2000-04-12 |
2005-09-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050100991A1
(en)
*
|
2001-04-12 |
2005-05-12 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
WO2002051432A1
(en)
*
|
2001-11-16 |
2002-07-04 |
New River Pharmaceuticals Inc. |
A novel pharmaceutical compound and methods of making and using same
|
US7163918B2
(en)
|
2000-08-22 |
2007-01-16 |
New River Pharmaceuticals Inc. |
Iodothyronine compositions
|
US20020099013A1
(en)
*
|
2000-11-14 |
2002-07-25 |
Thomas Piccariello |
Active agent delivery systems and methods for protecting and administering active agents
|
WO2003020200A2
(en)
*
|
2000-11-16 |
2003-03-13 |
New River Pharmaceuticals Inc. |
A novel pharmaceutical compound and methods of making and using same
|
AU8844301A
(en)
*
|
2000-08-29 |
2002-03-13 |
Univ Colorado State Res Found |
Method for treating the central nervous system by administration of igf structural analogs
|
US7067550B2
(en)
*
|
2000-11-03 |
2006-06-27 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in Alzheimer's Disease
|
EP1341548A4
(de)
*
|
2000-11-03 |
2006-06-14 |
Massachusetts Inst Technology |
VERFAHREN ZUR IDENTIFIZIERUNG VON BEHANDLUNGEN GEGEN NEUROTOXIZITÄT BEI ALZHEIMER-KRANKHEIT, DIE DURCH $g(b)-AMYLOIDPEPTIDE HERVORGERUFEN WIRD
|
US8394813B2
(en)
*
|
2000-11-14 |
2013-03-12 |
Shire Llc |
Active agent delivery systems and methods for protecting and administering active agents
|
JP2006516947A
(ja)
*
|
2000-11-16 |
2006-07-13 |
ニュー リバー ファーマシューティカルズ インコーポレイテッド |
新規な医薬化合物およびその製造方法と使用方法
|
AU2002246580A1
(en)
*
|
2000-12-04 |
2002-07-24 |
The Regents Of The University Of California |
Antisense imaging of gene expression of the brain in vivo
|
WO2002051428A1
(fr)
*
|
2000-12-25 |
2002-07-04 |
Shiseido Company, Ltd. |
Composition de parfum stimulant le systeme sympathique
|
US20040121947A1
(en)
*
|
2000-12-28 |
2004-06-24 |
Oklahoma Medical Research Foundation |
Compounds which inhibit beta-secretase activity and methods of use thereof
|
US6867183B2
(en)
*
|
2001-02-15 |
2005-03-15 |
Nobex Corporation |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US7507413B2
(en)
|
2001-04-12 |
2009-03-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20060084794A1
(en)
*
|
2001-04-12 |
2006-04-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050244931A1
(en)
*
|
2001-04-12 |
2005-11-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050054051A1
(en)
*
|
2001-04-12 |
2005-03-10 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7629309B2
(en)
*
|
2002-05-29 |
2009-12-08 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
US20040005309A1
(en)
*
|
2002-05-29 |
2004-01-08 |
Symbiontics, Inc. |
Targeted therapeutic proteins
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
ATE384736T1
(de)
*
|
2001-04-30 |
2008-02-15 |
Zystor Therapeutics Inc |
Subzelluläres targeting von therapeutischen proteinen
|
US6835802B2
(en)
*
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US6858580B2
(en)
*
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6828297B2
(en)
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6713452B2
(en)
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6828305B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7713932B2
(en)
*
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
US20070066537A1
(en)
*
|
2002-02-22 |
2007-03-22 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US7169752B2
(en)
*
|
2003-09-30 |
2007-01-30 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US7338939B2
(en)
*
|
2003-09-30 |
2008-03-04 |
New River Pharmaceuticals Inc. |
Abuse-resistant hydrocodone compounds
|
US7375082B2
(en)
*
|
2002-02-22 |
2008-05-20 |
Shire Llc |
Abuse-resistant hydrocodone compounds
|
US20060014697A1
(en)
*
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
AR036400A1
(es)
*
|
2001-08-30 |
2004-09-08 |
Stem Cell Therapeutics Inc |
Regulacion combinada de la produccion de celulas nerviosas.
|
US7196059B2
(en)
*
|
2001-09-07 |
2007-03-27 |
Biocon Limited |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
ES2383169T3
(es)
*
|
2001-09-14 |
2012-06-18 |
Stem Cell Therapeutics Inc. |
Aumento del número de células madre neurales inducido por prolactina y uso terapéutico del mismo
|
WO2003024471A2
(en)
*
|
2001-09-18 |
2003-03-27 |
Stem Cell Therapeutics Inc. |
Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
|
AU2002332041A1
(en)
*
|
2001-10-05 |
2003-04-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20030072761A1
(en)
*
|
2001-10-16 |
2003-04-17 |
Lebowitz Jonathan |
Methods and compositions for targeting proteins across the blood brain barrier
|
WO2003032727A1
(en)
*
|
2001-10-16 |
2003-04-24 |
Symbiontics Inc. |
Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
|
CA2464736A1
(en)
*
|
2001-10-23 |
2003-05-15 |
Oklahoma Medical Research Foundation |
Beta-secretase inhibitors and methods of use
|
US20060234944A1
(en)
*
|
2001-10-23 |
2006-10-19 |
Oklahoma Medical Reseach Foundation |
Beta-secretase inhibitors and methods of use
|
EP1506400A2
(de)
*
|
2001-10-30 |
2005-02-16 |
President And Fellows Of Harvard College |
Pfad für die rantes-vermittelte chemokin-synthese in astrocyten und anwendungsverfahren dafür
|
EP1463752A4
(de)
*
|
2001-12-21 |
2005-07-13 |
Human Genome Sciences Inc |
Albuminfusionsproteine
|
CA2471363C
(en)
*
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7659253B2
(en)
*
|
2002-02-22 |
2010-02-09 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
AU2003219863C1
(en)
*
|
2002-02-22 |
2009-03-05 |
Shire Llc |
Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
|
KR20050010756A
(ko)
*
|
2002-02-22 |
2005-01-28 |
뉴 리버 파마슈티칼스, 인크. |
피험자 간 약물 혈청 농도의 변동성을 감소시키기 위한펩티드-약물 접합체의 용도
|
US7700561B2
(en)
*
|
2002-02-22 |
2010-04-20 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
US7105486B2
(en)
*
|
2002-02-22 |
2006-09-12 |
New River Pharmaceuticals Inc. |
Abuse-resistant amphetamine compounds
|
NZ535275A
(en)
*
|
2002-03-04 |
2007-03-30 |
Nymox Corp |
Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, and treatments and animal models produced therefrom
|
US7332585B2
(en)
*
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
AU2003236521A1
(en)
*
|
2002-06-13 |
2003-12-31 |
Nobex Corporation |
Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
|
CA2492442A1
(en)
*
|
2002-07-31 |
2004-02-05 |
Stem Cell Therapeutics Inc. |
Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
|
US20040102369A1
(en)
*
|
2002-11-27 |
2004-05-27 |
The Regents Of The University Of California |
Transport of basic fibroblast growth factor across the blood brain barrier
|
US7388079B2
(en)
*
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
DK1583562T3
(da)
*
|
2003-01-06 |
2011-09-19 |
Angiochem Inc |
Angiopep-1, beslægtede forbindelser og anvendelser deraf
|
CA2513213C
(en)
|
2003-01-22 |
2013-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
AU2004251647B2
(en)
|
2003-05-29 |
2010-01-14 |
Takeda Pharmaceutical Company Limited |
Abuse resistant amphetamine compounds
|
CA2525236C
(en)
*
|
2003-06-20 |
2015-03-24 |
Biomarin Pharmaceutical Inc. |
Delivery of therapeutic compounds to the brain and other tissues
|
US20050026823A1
(en)
*
|
2003-06-20 |
2005-02-03 |
Biomarin Pharmaceutical Inc. |
Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
|
US7442372B2
(en)
|
2003-08-29 |
2008-10-28 |
Biomarin Pharmaceutical Inc. |
Delivery of therapeutic compounds to the brain and other tissues
|
US8668926B1
(en)
|
2003-09-15 |
2014-03-11 |
Shaker A. Mousa |
Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
|
US8071134B2
(en)
|
2003-09-15 |
2011-12-06 |
Ordway Research Institute, Inc. |
Thyroid hormone analogs and methods of use
|
US9198887B2
(en)
|
2003-09-15 |
2015-12-01 |
Nanopharmaceuticals Llc |
Thyroid hormone analogs and methods of use
|
EP1670449B1
(de)
*
|
2003-09-15 |
2012-06-27 |
Ordway Research Institute, Inc. |
Schilddrüsenhormon-analoga und anwendungsverfahren in der angiogenese
|
EA008864B1
(ru)
*
|
2003-09-30 |
2007-08-31 |
Нью Ривер Фармасьютикалз Инк. |
Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
|
NZ548529A
(en)
*
|
2003-12-16 |
2010-08-27 |
Nektar Therapeutics |
Pegylated small molecules
|
US20060182692A1
(en)
|
2003-12-16 |
2006-08-17 |
Fishburn C S |
Chemically modified small molecules
|
CN1922313B
(zh)
*
|
2004-02-10 |
2011-10-26 |
生物马林医药公司 |
酸性α-糖苷酶及其片段
|
WO2005077404A1
(en)
|
2004-02-13 |
2005-08-25 |
Stem Cell Therapeutics Corp. |
Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
|
WO2005117992A2
(en)
*
|
2004-05-30 |
2005-12-15 |
Cemines, Inc. |
Controlled delivery of therapeutic compounds
|
CA2580313C
(en)
*
|
2004-07-19 |
2016-03-15 |
Biocon Limited |
Insulin-oligomer conjugates, formulations and uses thereof
|
WO2006034296A2
(en)
*
|
2004-09-17 |
2006-03-30 |
Comentis, Inc. |
Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
|
JP2008513495A
(ja)
*
|
2004-09-17 |
2008-05-01 |
コメンティス,インコーポレーテッド |
ベータ−セクレターゼ活性を阻害する二環式化合物およびその使用方法
|
US20090016959A1
(en)
*
|
2005-02-18 |
2009-01-15 |
Richard Beliveau |
Delivery of antibodies to the central nervous system
|
ES2383901T5
(es)
*
|
2005-02-18 |
2015-02-25 |
Angiochem Inc. |
Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro
|
JP2008535863A
(ja)
*
|
2005-04-08 |
2008-09-04 |
コメンティス,インコーポレーテッド |
β−セクレターゼ活性を阻害する化合物およびその使用方法
|
ES2424242T3
(es)
|
2005-07-15 |
2013-09-30 |
Angiochem Inc. |
Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
|
CU23317A1
(es)
|
2005-07-22 |
2008-10-22 |
Ct De Investigacia N Y Desarro |
Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
|
EP1957093B1
(de)
|
2005-08-29 |
2017-04-12 |
SHASHOUA, Victor E. |
Neuroprotektive und neurorestorative verfahren und zusammensetzungen
|
US9220788B2
(en)
*
|
2009-06-17 |
2015-12-29 |
Nanopharmaceuticals Llc |
Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
|
US20090022806A1
(en)
*
|
2006-12-22 |
2009-01-22 |
Mousa Shaker A |
Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
|
US9498536B2
(en)
|
2005-09-15 |
2016-11-22 |
Nanopharmaceuticals Llc |
Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
|
US10130686B2
(en)
|
2005-09-15 |
2018-11-20 |
Nanopharmaceuticals Llc |
Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
|
US20100209382A1
(en)
|
2005-09-16 |
2010-08-19 |
Ordway Research Institute, Inc. |
Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
|
WO2007036033A1
(en)
*
|
2005-09-27 |
2007-04-05 |
Stem Cell Therapeutics Corp. |
Oligodendrocyte precursor cell proliferation regulated by prolactin
|
US8053569B2
(en)
*
|
2005-10-07 |
2011-11-08 |
Armagen Technologies, Inc. |
Nucleic acids encoding and methods of producing fusion proteins
|
US8124095B2
(en)
*
|
2005-10-07 |
2012-02-28 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of erythropoietin to the CNS
|
US8741260B2
(en)
*
|
2005-10-07 |
2014-06-03 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of GDNF to the CNS
|
WO2007049940A1
(en)
*
|
2005-10-27 |
2007-05-03 |
Peptron Co., Ltd |
Bioactive substance-blood protein conjugate and stabilization of a bioactive substance using the same
|
AU2007229301B2
(en)
*
|
2006-03-17 |
2013-08-01 |
Stem Cell Therapeutics Corp. |
Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
|
US8759297B2
(en)
*
|
2006-08-18 |
2014-06-24 |
Armagen Technologies, Inc. |
Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
|
CA2669347A1
(en)
*
|
2006-11-13 |
2008-05-29 |
Zystor Therapeutics, Inc. |
Methods for treating pompe disease
|
WO2008140493A2
(en)
*
|
2006-11-21 |
2008-11-20 |
The Regents Of The University Of Californina |
Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
|
JP2010513526A
(ja)
*
|
2006-12-22 |
2010-04-30 |
シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド |
甲状腺ホルモン類縁体、拮抗剤および製剤のためのナノ粒子及び重合体製剤ならびにその使用
|
WO2008137066A1
(en)
*
|
2007-05-02 |
2008-11-13 |
The Board Of Regents Of The University Of Oklahoma |
Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
|
EP2486849A3
(de)
|
2007-05-16 |
2014-11-05 |
Yeda Research and Development Co. Ltd. |
Beurteilung einer Störung der Blut-Gehirn-Schranke
|
US9365634B2
(en)
*
|
2007-05-29 |
2016-06-14 |
Angiochem Inc. |
Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
|
KR20100051668A
(ko)
*
|
2007-07-26 |
2010-05-17 |
코멘티스, 인코포레이티드 |
베타-세크레타제 활성을 억제하는 이소프탈아미드 유도체
|
AU2008282496B2
(en)
|
2007-07-27 |
2013-04-04 |
Armagen Technologies, Inc. |
Methods and compositions for increasing alpha-iduronidase activity in the CNS
|
CA2699787A1
(en)
*
|
2007-09-24 |
2009-04-02 |
Comentis, Inc. |
(3-hydroxy-4-amino-butan-2-yl)-3-(2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating
|
JP5868594B2
(ja)
*
|
2007-10-16 |
2016-02-24 |
バイオコン・リミテッドBiocon Limited |
経口投与可能な固形医薬組成物及びそのプロセス
|
JP5860698B2
(ja)
*
|
2008-04-18 |
2016-02-16 |
アンジオケム,インコーポレーテッド |
パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法
|
EP3778652A1
(de)
|
2008-05-07 |
2021-02-17 |
BioMarin Pharmaceutical Inc. |
Auf lysosomen gerichtete peptide und verwendungen davon
|
BRPI0920209A2
(pt)
|
2008-10-15 |
2015-12-22 |
Angiochem Inc |
conjugados de agonistas de glp-1 e usos dos mesmos
|
RU2531591C2
(ru)
|
2008-10-15 |
2014-10-20 |
Ангиокем Инк. |
Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
|
US9914754B2
(en)
*
|
2008-12-05 |
2018-03-13 |
Angiochem Inc. |
Conjugates of neurotensin or neurotensin analogs and uses thereof
|
MX2011006685A
(es)
|
2008-12-17 |
2011-09-27 |
Angiochem Inc |
Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.
|
WO2010075332A1
(en)
*
|
2008-12-23 |
2010-07-01 |
Charitable Leadership Foundation |
Small molecule ligands of the integrin rgd recognition site and methods of use
|
US9533055B2
(en)
|
2009-03-18 |
2017-01-03 |
Armagen Technologies, Inc. |
Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
|
WO2010120506A1
(en)
*
|
2009-03-31 |
2010-10-21 |
Ordway Research Institute, Inc. |
Combination treatment of cancer with cetuximab and tetrac
|
ES2729261T3
(es)
|
2009-04-20 |
2019-10-31 |
Angiochem Inc |
Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
|
US8785168B2
(en)
|
2009-06-17 |
2014-07-22 |
Biomarin Pharmaceutical Inc. |
Formulations for lysosomal enzymes
|
IN2012DN00248A
(de)
|
2009-07-02 |
2015-05-01 |
Angiochem Inc |
|
WO2011013128A2
(en)
|
2009-07-31 |
2011-02-03 |
Yeda Research And Development Co. Ltd. |
Vectors for delivery of neurotherapeutics to the central nervous system
|
CA2772023A1
(en)
|
2009-08-18 |
2011-02-24 |
Ben Gurion University Of The Negev Research And Development Authority |
System and method for analyzing imaging data
|
HUE044865T2
(hu)
|
2009-10-09 |
2019-11-28 |
Armagen Inc |
Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére
|
EP3252068A3
(de)
|
2009-10-12 |
2018-03-14 |
Larry J. Smith |
Verfahren und zusammensetzungen zur modulation der genexpression unter verwendung in-vivo- oder in-vitro-verabreichten arzneistoffen auf oligonukleotidbasis
|
EP2646470B1
(de)
|
2010-11-30 |
2017-03-01 |
F. Hoffmann-La Roche AG |
Antikörper gegen transferin rezeptor mit niedriger affinität und ihre verwendungen zur überwindung der bluthirnschranke
|
US8802240B2
(en)
|
2011-01-06 |
2014-08-12 |
Nanopharmaceuticals Llc |
Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
|
SG10201601324VA
(en)
*
|
2011-09-04 |
2016-03-30 |
Glytech Inc |
Glycosylated polypeptide and drug composition containing said polypeptide
|
EP2768386B1
(de)
|
2011-10-19 |
2024-04-03 |
Tel HaShomer Medical Research Infrastructure and Services Ltd. |
Magnetresonanzkarten zur analyse von gewebe
|
EP3711778B1
(de)
|
2011-12-02 |
2024-05-08 |
Armagen, Inc. |
Verfahren und zusammensetzungen für erhöhte sulfatase-a-aktivität im zns
|
CN115778934A
(zh)
|
2012-01-20 |
2023-03-14 |
德玛公司 |
经取代的己糖醇类用于治疗恶性肿瘤的用途
|
US10809323B2
(en)
|
2013-04-24 |
2020-10-20 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Magnetic resonance maps for analyzing tissue
|
TW201536278A
(zh)
*
|
2013-05-31 |
2015-10-01 |
Del Mar Pharmaceuticals |
雙脫水半乳糖醇及其類似物與衍生物用於治療復發性惡性神經膠瘤或進行性繼發腦瘤之用途
|
WO2015074050A1
(en)
|
2013-11-18 |
2015-05-21 |
Nanopharmaceuticals Llc |
Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
|
GB201321242D0
(en)
|
2013-12-02 |
2014-01-15 |
Immune Targeting Systems Its Ltd |
Immunogenic compound
|
KR102456088B1
(ko)
|
2014-04-04 |
2022-10-19 |
델 마 파마슈티컬스 |
폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
|
BR112017009845A2
(pt)
*
|
2014-11-10 |
2018-01-16 |
Del Mar Pharmaceuticals |
dianidrogalactitol juntamente com radiação para tratar carcinoma de célula não pequena dos pulmões e glioblastoma multiforme
|
US10538589B2
(en)
|
2015-01-14 |
2020-01-21 |
Armagen Inc. |
Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
|
ES2826827T3
(es)
|
2015-06-15 |
2021-05-19 |
Angiochem Inc |
Métodos para el tratamiento de carcinomatosis leptomeníngea
|
CN109715551A
(zh)
|
2016-06-07 |
2019-05-03 |
纳米药业有限责任公司 |
与αvβ3整联蛋白甲状腺拮抗剂缀合的不可裂解聚合物
|
US10328043B1
(en)
|
2018-04-11 |
2019-06-25 |
Nanopharmaceuticals, Llc. |
Composition and method for dual targeting in treatment of neuroendocrine tumors
|
US11351137B2
(en)
|
2018-04-11 |
2022-06-07 |
Nanopharmaceuticals Llc |
Composition and method for dual targeting in treatment of neuroendocrine tumors
|
US10961204B1
(en)
|
2020-04-29 |
2021-03-30 |
Nanopharmaceuticals Llc |
Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
|
US11723888B2
(en)
|
2021-12-09 |
2023-08-15 |
Nanopharmaceuticals Llc |
Polymer conjugated thyrointegrin antagonists
|
CN115894719B
(zh)
*
|
2022-11-24 |
2023-10-20 |
武汉禾元生物科技股份有限公司 |
一种人血清白蛋白胰岛素偶联物及其制备方法
|